The U.S.'s Federal Trade Commission is the last major Western regulator that needs to give its approval. However, there may be concerns surrounding China's decision. In recent weeks, Chinese regulators failed to approve Intel's planned acquisition of Tower Semiconductor, causing apprehension about clearance for the Broadcom deal. Mergers trigger an antitrust review in China if the companies involved earn over $117 million in annual revenue from within the country. Considering Broadcom's substantial revenue from China, obtaining clearance may prove challenging.

While China's antitrust review process has raised concerns about potential roadblocks, it is important to note that there is no reason to assume that the same outcome will occur in the Broadcom case. Moreover, this deal differs from most semiconductor industry mergers, as it involves a significant expansion outside of the industry. Furthermore, China has previously approved large-scale mergers involving U.S. companies, such as Microsoft's acquisition of Activision, indicating a willingness to support such deals.

Broadcom anticipates receiving final regulatory approvals, including from the FTC, by October 30. The company remains committed to working constructively with regulators in other jurisdictions and is currently in the advanced stages of obtaining the remaining required regulatory approvals.

Broadcom shares experienced a 0.2% increase in premarket trading, while VMware shares surged by 6.6%.

The Importance of Free Cash Flow for Chinese EV Maker XPeng

Willow Biosciences' Collaboration Announcement

Leave A Reply

Your email address will not be published. Required fields are marked *

Related posts

Investors Optimistic as Money Continues to Flow Into Stocks
News

Investors Optimistic as Money Continues to Flow Into Stocks

Investors are confident in the Fed's actions, leading to increased funds in stocks. Outlook for 2024 and opportunities f...

Sanofi Aims for Annual Sales of Over 10 Billion Euros by 2030
News

Sanofi Aims for Annual Sales of Over 10 Billion Euros by 2030

Sanofi sets a target of generating over 10 billion euros in annual sales by 2030, focusing on immunology treatments and...

Oracle's Cloud Business Drives 40% Rally in Shares
News

Oracle's Cloud Business Drives 40% Rally in Shares

Oracle's shares have surged by 40% due to its thriving cloud business. However, integrating Cerner poses challenges. Ora...

Chevron: A Resilient Energy Company
News

Chevron: A Resilient Energy Company

Chevron continues to be a leading energy company despite facing challenges in 2023. Its stock may be undervalued with a...